Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatmen... Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD). Mehr anzeigen
Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC Completed approximately $100 million public offering, extending runway into 2027 Initial data from...
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.08 | -18.9141856392 | 5.71 | 5.94 | 4.56 | 362488 | 5.07282017 | CS |
| 4 | -0.52 | -10.0970873786 | 5.15 | 6.2 | 4.56 | 475772 | 5.45532119 | CS |
| 12 | 2.76 | 147.593582888 | 1.87 | 10.48 | 1.8 | 2551218 | 5.82608791 | CS |
| 26 | 2.23 | 92.9166666667 | 2.4 | 10.48 | 1.595 | 1221648 | 5.55577044 | CS |
| 52 | 2.35 | 103.070175439 | 2.28 | 10.48 | 1.595 | 750247 | 5.14914111 | CS |
| 156 | -1.62 | -25.92 | 6.25 | 10.48 | 1.04 | 274190 | 4.97052519 | CS |
| 260 | -23.71 | -83.6626676076 | 28.34 | 67.079 | 1.04 | 206195 | 6.58946279 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
